Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition

References

• Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–10. doi: 10.1158/1078-0432.CCR-09-1624.
   PubMed Web of Science ®Google Scholar
• Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19(14):3936–3943. doi: 10.1158/1078-0432.CCR-13-0895.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e152. doi: 10.1016/S1470-2045(17)30074-8.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–1639. doi: 10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Chiou VL, Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol. 2015;33(31):3541–3543. doi: 10.1200/JCO.2015.61.6870.
   PubMed Web of Science ®Google Scholar
• Chen MY, Zeng YC. Pseudoprogression in lung cancer patients treated with immunotherapy. Crit Rev Oncol Hematol. 2022;169:103531. doi: 10.1016/j.critrevonc.2021.103531.
   PubMed Web of Science ®Google Scholar
• Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria J-C. et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920–1928. doi: 10.1158/1078-0432.CCR-16-1741.
   PubMed Web of Science ®Google Scholar
• Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S. et al. Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4(11):1543–1552. doi: 10.1001/jamaoncol.2018.3676.
   PubMed Web of Science ®Google Scholar
• Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH, Ahn BC, Kim Y, Choi SJ, Yoon HI, Lee JG. et al. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019;30(7):1104–1113. doi: 10.1093/annonc/mdz123.
   PubMed Web of Science ®Google Scholar
• Ruiz-Patiño A, Arrieta O, Cardona AF, Martín C, Raez LE, Zatarain-Barrón ZL, Barrón F, Ricaurte L, Bravo-Garzón MA, Mas L. et al. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (quijote-CLICaP). Thorac Cancer. 2020;11(2):353–361. doi: 10.1111/1759-7714.13272.
   PubMed Web of Science ®Google Scholar
• Sehgal K. Hyperprogression in patients with cancer receiving immune checkpoint inhibitors. JAMA Netw Open. 2021;4(3):e211839. doi: 10.1001/jamanetworkopen.2021.1839.
   PubMed Web of Science ®Google Scholar
• Ito K, Hataji O, Katsuta K, Kobayashi T, Gabazza EC, Yatabe Y, Taguchi O, Yamamoto N. “Pseudoprogression” of pulmonary pleomorphic carcinoma during nivolumab therapy. J Thorac Oncol. 2016;11(10):e117–e119. doi: 10.1016/j.jtho.2016.05.002.
   PubMed Web of Science ®Google Scholar
• Rocha P, Hardy-Werbin M, Naranjo D, Taus Á, Rodrigo M, Zuccarino F, Roth R, Wood O, Ottensmeier CH, Arriola E. CD103+CD8+ lymphocytes characterize the immune infiltration in a case with pseudoprogression in squamous NSCLC. J Thorac Oncol. 2018;13(10):e193–e196. doi: 10.1016/j.jtho.2018.05.008.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Longo DL, Chabner BA. Pharmacodynamic biomarkers: falling short of the mark? Clin Cancer Res. 2014;20(10):2587–2594. doi: 10.1158/1078-0432.Ccr-13-3132.
   PubMed Web of Science ®Google Scholar
• Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242–4250. doi: 10.1158/1078-0432.CCR-16-3133.
   PubMed Web of Science ®Google Scholar
• Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, Wei S, Grove S, Vatan L, Nelson R. et al. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer Cell. 2023;41(2):304–322.e307. doi: 10.1016/j.ccell.2022.12.008.
   PubMed Web of Science ®Google Scholar
• Stadler JC, Belloum Y, Deitert B, Sementsov M, Heidrich I, Gebhardt C, Keller L, Pantel K. Current and future clinical applications of ctDNA in immuno-oncology. Cancer Res. 2022;82(3):349–358. doi: 10.1158/0008-5472.Can-21-1718.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S. et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol. 2017;28(8):1988–1995. doi: 10.1093/annonc/mdx190.
   PubMed Web of Science ®Google Scholar
• Matsuo N, Azuma K, Hattori S, Ohtake J, Kawahara A, Ishii H, Tokito T, Yamada K, Shibata Y, Shimokawaji T. et al. Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor. Int J Cancer. 2019;144(5):1170–1179. doi: 10.1002/ijc.31923.
   PubMed Web of Science ®Google Scholar
• Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, Katsurada N, Tachihara M, Kobayashi K, Nishimura Y. Pseudo-progression and the neutrophil-to-lymphocyte ratio in non-small cell lung cancer treated with immune checkpoint inhibitors: a case-control study. Onco Targets Ther. 2019;12:10559–10568. doi: 10.2147/OTT.S228138.
   PubMed Web of Science ®Google Scholar
• Choi WM, Kim JY, Choi J, Lee D, Shim JH, Lim YS, Lee HC, Yoo C, Ryu MH, Ryoo BY. et al. Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. Liver Int. 2021;41(9):2189–2199. doi: 10.1111/liv.14932.
   PubMed Web of Science ®Google Scholar
• Guiot J, Vaidyanathan A, Deprez L, Zerka F, Danthine D, Frix AN, Lambin P, Bottari F, Tsoutzidis N, Miraglio B. et al. A review in radiomics: making personalized medicine a reality via routine imaging. Med Res Rev. 2022;42(1):426–440. doi: 10.1002/med.21846.
   PubMed Web of Science ®Google Scholar
• Khorrami M, Bera K, Thawani R, Rajiah P, Gupta A, Fu P, Linden P, Pennell N, Jacono F, Gilkeson RC. et al. Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans. Eur J Cancer. 2021;148:146–158. doi: 10.1016/j.ejca.2021.02.008.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu J, Yang X, Wang A, Zang C, Wang L, He C, Lin L, Qing H, Ren J. et al. An ordinal radiomic model to predict the differentiation grade of invasive non-mucinous pulmonary adenocarcinoma based on low-dose computed tomography in lung cancer screening. Eur Radiol. 2023;33(5):3072–3082. doi: 10.1007/s00330-023-09453-y.
   PubMed Web of Science ®Google Scholar
• Jazieh K, Khorrami M, Saad A, Gad M, Gupta A, Patil P, Viswanathan VS, Rajiah P, Nock CJ, Gilkey M. et al. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. J Immunother Cancer. 2022;10(3):e003778. doi: 10.1136/jitc-2021-003778.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Chen M, Hu G, Pan Z, Han W, Tan W, Zhou Z, Wang M, Mao L, Li X. et al. A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer. Eur Radiol. 2023;33(6):3918–3930. doi: 10.1007/s00330-022-09337-7.
   PubMed Web of Science ®Google Scholar
• Akhoundova D, Hiltbrunner S, Mader C, Förster R, Kraft J, Schwanhäusser B, Bankel L, Kollias S, Treyer V, Rushing EJ. et al. 18F-FET PET for diagnosis of pseudoprogression of brain metastases in patients with non-small cell lung cancer. Clin Nucl Med. 2020;45(2):113–117. doi: 10.1097/RLU.0000000000002890.
   PubMed Web of Science ®Google Scholar
• Vaidya P, Bera K, Patil PD, Gupta A, Jain P, Alilou M, Khorrami M, Velcheti V, Madabhushi A. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade. J Immunother Cancer. 2020;8(2). doi: 10.1136/jitc-2020-001343.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Hwu W-J, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC. et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab. J Clin Oncol. 2016;34(13):1510–1517. doi: 10.1200/JCO.2015.64.0391.
   PubMed Web of Science ®Google Scholar
• Mu W, Schabath MB, Gillies RJ. Images are data: challenges and opportunities in the clinical translation of radiomics. Cancer Res. 2022;82(11):2066–2068. doi: 10.1158/0008-5472.Can-22-1183.
   PubMed Web of Science ®Google Scholar
• Zhou Z-H. Machine learning. Singapore: Springer Nature; 2021.
   Google Scholar
• Chen Q, Zhang L, Mo X, You J, Chen L, Fang J, Wang F, Jin Z, Zhang B, Zhang S. Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;49(1):345–360. doi: 10.1007/s00259-021-05509-7.
   PubMed Web of Science ®Google Scholar
• Tian P, He B, Mu W, Liu K, Liu L, Zeng H, Liu Y, Jiang L, Zhou P, Huang Z. et al. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images. Theranostics. 2021;11(5):2098–2107. doi: 10.7150/thno.48027.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M. et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58(8):1297–1306. doi: 10.1007/s00262-008-0642-y.
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Hayashi H, Kimura M, Tanaka K, Takeda M, Shimizu S, Ito A, Nakagawa K. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. Lung Cancer. 2016;102:44–48. doi: 10.1016/j.lungcan.2016.10.014.
   PubMed Web of Science ®Google Scholar
• Dercle L, Sun S, Seban RD, Mekki A, Sun R, Tselikas L, Hans S, Bernard-Tessier A, Mihoubi Bouvier F, Aide N. et al. Emerging and evolving concepts in cancer immunotherapy imaging. Radiology. 2023;306(1):32–46. doi: 10.1148/radiol.210518.
   PubMed Web of Science ®Google Scholar
• Digernes I, Grøvik E, Nilsen LB, Saxhaug C, Geier O, Reitan E, Sætre DO, Breivik B, Reese T, Jacobsen KD. et al. Brain metastases with poor vascular function are susceptible to pseudoprogression after stereotactic radiation surgery. Adv Radiat Oncol. 2018;3(4):559–567. doi: 10.1016/j.adro.2018.05.005.
   PubMedGoogle Scholar
• Walker AJ, Ruzevick J, Malayeri AA, Rigamonti D, Lim M, Redmond KJ, Kleinberg L. Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression? Future Oncol (London, England). 2014;10(7):1277–1297. doi: 10.2217/fon.13.271.
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Fortis SP, Perez SA. The balance between breast cancer and the immune system: challenges for prognosis and clinical benefit from immunotherapies. Semin Cancer Biol. 2021;72:76–89. doi: 10.1016/j.semcancer.2019.12.018.
   PubMed Web of Science ®Google Scholar
• Perrone M, Raimondi E, Costa M, Rasetto G, Rizzati R, Lanza G, Gafà R, Cavallesco G, Tamburini N, Maniscalco P. et al. Inflammatory microenvironment in early non-small cell lung cancer: exploring the predictive value of radiomics. Cancers Basel. 2022;14(14). doi: 10.3390/cancers14143335.
   Web of Science ®Google Scholar
• Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S. et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19(9):1180–1191. doi: 10.1016/S1470-2045(18)30413-3.
   PubMed Web of Science ®Google Scholar
• He LN, Chen T, Fu S, Jiang Y, Zhang X, Chen C, Du W, Luo L, Li A, Wang Y. et al. Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor. Ther Adv Med Oncol. 2023;15:17588359231200463. doi: 10.1177/17588359231200463.
   Web of Science ®Google Scholar
• Li LX, Cappuzzo F, Matos I, Socinski MA, Hopkins AM, Sorich MJ. Low risk of hyperprogression with first-line chemoimmunotherapy for advanced non-small cell lung cancer: pooled analysis of 7 clinical trials. Oncologist. 2023;28(4):e205–e211. doi: 10.1093/oncolo/oyad043.
   PubMedGoogle Scholar
• Lin M, Vanneste BGL, Yu Q, Chen Z, Peng J, Cai X. Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review. Transl Lung Cancer Res. 2021;10(7):3276–3291. doi: 10.21037/tlcr-21-575.
   PubMed Web of Science ®Google Scholar
• Liu J, Wu Q, Wu S, Xie X. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs). Clinical & translational oncology: official publication of the Federation of Spanish oncology societies and of the national cancer institute of Mexico. 2021;23(9):1782–1793. doi: 10.1007/s12094-021-02579-9.
   Google Scholar
• Li J, Zhang H, Zhu H, Li H. Clinical outcomes and immunological evaluation of toripalimab combination for cancer treatment: a systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2023;125(Pt B):111176. doi: 10.1016/j.intimp.2023.111176.
   PubMedGoogle Scholar
• Wakiyama H, Kato T, Furusawa A, Okada R, Inagaki F, Furumoto H, Fukushima H, Okuyama S, Choyke PL, Kobayashi H. Treg-dominant tumor microenvironment is responsible for hyperprogressive disease after PD-1 blockade therapy. Cancer Immunol Res. 2022;10(11):1386–1397. doi: 10.1158/2326-6066.Cir-22-0041.
   PubMed Web of Science ®Google Scholar
• Jiang T, Song J, Wang X, Niu S, Zhao N, Dong Y, Wang X, Luo Y, Jiang X. Intratumoral and peritumoral analysis of mammography, Tomosynthesis, and multiparametric MRI for predicting ki-67 level in breast cancer: a radiomics-based study. Mol Imaging Biol. 2022;24(4):550–559. doi: 10.1007/s11307-021-01695-w.
   PubMed Web of Science ®Google Scholar
• Tran KA, Kondrashova O, Bradley A, Williams ED, Pearson JV, Waddell N. Deep learning in cancer diagnosis, prognosis and treatment selection. Genome Med. 2021;13(1):152. doi: 10.1186/s13073-021-00968-x.
   PubMed Web of Science ®Google Scholar
• Painuli D, Bhardwaj S, Köse U. Recent advancement in cancer diagnosis using machine learning and deep learning techniques: A comprehensive review. Comput Biol Med. 2022;146:105580. doi: 10.1016/j.compbiomed.2022.105580.
   PubMed Web of Science ®Google Scholar
• Feng Z, Li H, Liu Q, Duan J, Zhou W, Yu X, Chen Q, Liu Z, Wang W, Rong P. CT radiomics to predict macrotrabecular-massive subtype and immune status in hepatocellular carcinoma. Radiology. 2023;307(1):e221291. doi: 10.1148/radiol.221291.
   PubMed Web of Science ®Google Scholar
• Huang S, Yang J, Shen N, Xu Q, Zhao Q. Artificial intelligence in lung cancer diagnosis and prognosis: Current application and future perspective. Semin Cancer Biol. 2023;89:30–37. doi: 10.1016/j.semcancer.2023.01.006.
   PubMed Web of Science ®Google Scholar